スプートニクV COVID-19ワクチン (Japanese Wikipedia)

Callaway E (August 2020). “Russia's fast-track coronavirus vaccine draws outrage over safety”. Nature 584 (7821): 334–335. doi:10.1038/d41586-020-02386-2. PMID 32782400. "This is a reckless and foolish decision. Mass vaccination with an improperly tested vaccine is unethical. Any problem with the Russian vaccination campaign would be disastrous both through its negative effects on health, but also because it would further set back the acceptance of vaccines in the population."

ndtv.com

“Russia Approves Single-Dose Sputnik Light Covid Vaccine For Use”. NDTV Coronavirus. (6 May 2021)

nih.gov

pubmed.ncbi.nlm.nih.gov

Callaway E (August 2020). “Russia's fast-track coronavirus vaccine draws outrage over safety”. Nature 584 (7821): 334–335. doi:10.1038/d41586-020-02386-2. PMID 32782400. "This is a reckless and foolish decision. Mass vaccination with an improperly tested vaccine is unethical. Any problem with the Russian vaccination campaign would be disastrous both through its negative effects on health, but also because it would further set back the acceptance of vaccines in the population."
Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, Kovyrshina AV, Lubenets NL, Grousova DM, Erokhova AS, Botikov AG (2021-02-02). “Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia”. The Lancet. doi:10.1016/s0140-6736(21)00234-8. PMC 7852454. PMID 33545094.
Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatullin AI, Shcheblyakov DV, Dzharullaeva AS, Grousova DM, Erokhova AS, Kovyrshina AV, Botikov AG, Izhaeva FM, Popova O, Ozharovskaya TA, Esmagambetov IB, Favorskaya IA, Zrelkin DI, Voronina DV, Shcherbinin DN, Semikhin AS, Simakova YV, Tokarskaya EA, Lubenets NL, Egorova DA, Shmarov MM, Nikitenko NA, Morozova LF, Smolyarchuk EA, Kryukov EV, Babira VF, Borisevich SV, Naroditsky BS, Gintsburg AL (September 2020). “Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia”. Lancet 396 (10255): 887–897. doi:10.1016/S0140-6736(20)31866-3. PMC 7471804. PMID 32896291.
Mahase E (August 2020). “Covid-19: Russia approves vaccine without large scale testing or published results”. BMJ 370: m3205. doi:10.1136/bmj.m3205. PMID 32816758.
Burki TK (November 2020). “The Russian vaccine for COVID-19”. The Lancet. Respiratory Medicine 8 (11): e85–e86. doi:10.1016/S2213-2600(20)30402-1. PMC 7837053. PMID 32896274.
Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatullin AI, Shcheblyakov DV, Dzharullaeva AS, Grousova DM, Erokhova AS, Kovyrshina AV, Botikov AG, Izhaeva FM, Popova O, Ozharovskaya TA, Esmagambetov IB, Favorskaya IA, Zrelkin DI, Voronina DV, Shcherbinin DN, Semikhin AS, Simakova YV, Tokarskaya EA, Lubenets NL, Egorova DA, Shmarov MM, Nikitenko NA, Morozova LF, Smolyarchuk EA, Kryukov EV, Babira VF, Borisevich SV, Naroditsky BS, Gintsburg AL (September 2020). “Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia”. Lancet 396 (10255): 887–897. doi:10.1016/S0140-6736(20)31866-3. PMC 7471804. PMID 32896291.
Logunov DY, Dolzhikova IV, Tukhvatullin AI, Shcheblyakov DV (October 2020). “Safety and efficacy of the Russian COVID-19 vaccine: more information needed – Authors' reply”. Lancet 396 (10256): e54–e55. doi:10.1016/S0140-6736(20)31970-X. PMC 7503057. PMID 32971043.
Jones, Ian; Roy, Polly (2021-02-02). “Sputnik V COVID-19 vaccine candidate appears safe and effective” (English). The Lancet 0. doi:10.1016/S0140-6736(21)00191-4. ISSN 0140-6736. PMID 33545098.
Balakrishnan VS (1 October 2020). “The arrival of Sputnik V” (英語). The Lancet Infectious Diseases 20 (10): 1128. doi:10.1016/S1473-3099(20)30709-X. PMC 7511201. PMID 32979327.

pmc.ncbi.nlm.nih.gov

Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, Kovyrshina AV, Lubenets NL, Grousova DM, Erokhova AS, Botikov AG (2021-02-02). “Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia”. The Lancet. doi:10.1016/s0140-6736(21)00234-8. PMC 7852454. PMID 33545094.
Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatullin AI, Shcheblyakov DV, Dzharullaeva AS, Grousova DM, Erokhova AS, Kovyrshina AV, Botikov AG, Izhaeva FM, Popova O, Ozharovskaya TA, Esmagambetov IB, Favorskaya IA, Zrelkin DI, Voronina DV, Shcherbinin DN, Semikhin AS, Simakova YV, Tokarskaya EA, Lubenets NL, Egorova DA, Shmarov MM, Nikitenko NA, Morozova LF, Smolyarchuk EA, Kryukov EV, Babira VF, Borisevich SV, Naroditsky BS, Gintsburg AL (September 2020). “Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia”. Lancet 396 (10255): 887–897. doi:10.1016/S0140-6736(20)31866-3. PMC 7471804. PMID 32896291.
Burki TK (November 2020). “The Russian vaccine for COVID-19”. The Lancet. Respiratory Medicine 8 (11): e85–e86. doi:10.1016/S2213-2600(20)30402-1. PMC 7837053. PMID 32896274.
Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatullin AI, Shcheblyakov DV, Dzharullaeva AS, Grousova DM, Erokhova AS, Kovyrshina AV, Botikov AG, Izhaeva FM, Popova O, Ozharovskaya TA, Esmagambetov IB, Favorskaya IA, Zrelkin DI, Voronina DV, Shcherbinin DN, Semikhin AS, Simakova YV, Tokarskaya EA, Lubenets NL, Egorova DA, Shmarov MM, Nikitenko NA, Morozova LF, Smolyarchuk EA, Kryukov EV, Babira VF, Borisevich SV, Naroditsky BS, Gintsburg AL (September 2020). “Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia”. Lancet 396 (10255): 887–897. doi:10.1016/S0140-6736(20)31866-3. PMC 7471804. PMID 32896291.
Logunov DY, Dolzhikova IV, Tukhvatullin AI, Shcheblyakov DV (October 2020). “Safety and efficacy of the Russian COVID-19 vaccine: more information needed – Authors' reply”. Lancet 396 (10256): e54–e55. doi:10.1016/S0140-6736(20)31970-X. PMC 7503057. PMID 32971043.
Balakrishnan VS (1 October 2020). “The arrival of Sputnik V” (英語). The Lancet Infectious Diseases 20 (10): 1128. doi:10.1016/S1473-3099(20)30709-X. PMC 7511201. PMID 32979327.

ncbi.nlm.nih.gov

Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, Kovyrshina AV, Lubenets NL, Grousova DM, Erokhova AS, Botikov AG (2021-02-02). “Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia”. The Lancet. doi:10.1016/s0140-6736(21)00234-8. PMC 7852454. PMID 33545094.
Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatullin AI, Shcheblyakov DV, Dzharullaeva AS, Grousova DM, Erokhova AS, Kovyrshina AV, Botikov AG, Izhaeva FM, Popova O, Ozharovskaya TA, Esmagambetov IB, Favorskaya IA, Zrelkin DI, Voronina DV, Shcherbinin DN, Semikhin AS, Simakova YV, Tokarskaya EA, Lubenets NL, Egorova DA, Shmarov MM, Nikitenko NA, Morozova LF, Smolyarchuk EA, Kryukov EV, Babira VF, Borisevich SV, Naroditsky BS, Gintsburg AL (September 2020). “Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia”. Lancet 396 (10255): 887–897. doi:10.1016/S0140-6736(20)31866-3. PMC 7471804. PMID 32896291.
Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatullin AI, Shcheblyakov DV, Dzharullaeva AS, Grousova DM, Erokhova AS, Kovyrshina AV, Botikov AG, Izhaeva FM, Popova O, Ozharovskaya TA, Esmagambetov IB, Favorskaya IA, Zrelkin DI, Voronina DV, Shcherbinin DN, Semikhin AS, Simakova YV, Tokarskaya EA, Lubenets NL, Egorova DA, Shmarov MM, Nikitenko NA, Morozova LF, Smolyarchuk EA, Kryukov EV, Babira VF, Borisevich SV, Naroditsky BS, Gintsburg AL (September 2020). “Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia”. Lancet 396 (10255): 887–897. doi:10.1016/S0140-6736(20)31866-3. PMC 7471804. PMID 32896291.

nytimes.com

Kramer, Andrew. “Russia is offering to export hundreds of millions of vaccine doses, but can it deliver?”. nytimes.com. 20 February 2021閲覧。

rbc.ru

“Центр Гамалеи назвал сроки вакцинации большей части населения России”. RBK (September 4, 2020). 2020年9月6日閲覧。
“В России зарегистрировали вакцину «Спутник Лайт»” (ロシア語). РБК. 2021年5月7日閲覧。
“Минздрав пообещал россиянам бесплатную вакцинацию от COVID-19” [Ministry of Health promised Russians free vaccination against COVID-19] (ロシア語). RBC.ru. 2020年10月23日閲覧。

rdif.ru

“RDIF, The Gamaleya National Center, AstraZeneca and R-Pharm sign an agreement to cooperate on COVID-19 vaccine development”. The Russian Direct Investment Fund (21 December 2020). 2020年2月26日閲覧。
"Single dose vaccine, Sputnik Light, authorized for use in Russia" (Press release). Russian Direct Investment Fund. 6 May 2021. 2021年5月7日閲覧。

reuters.com

rg.ru

“В будущем вакцинация от COVID-19 будет проходить бесплатно” [In the future, vaccination against COVID-19 will be free of charge] (ロシア語). Russian Newspaper. 2020年10月23日閲覧。

ria.ru

“Глава РФПИ объяснил значение буквы "V" в названии "Спутника V"” (ロシア語). РИА Новости (2020年12月24日). 2021年5月28日閲覧。
“Минздрав зарегистрировал предельную отпускную цену на вакцину "Спутник V"” [The Ministry of Health registered the maximum selling price for the Sputnik V vaccine] (ロシア語). RIA (December 5, 2020). 2020年9月21日閲覧。

rosminzdrav.ru

grls.rosminzdrav.ru

“Нормативная документация ЛП-006395-110820” (ロシア語). Russian Ministry of Health (2020年). 2020年9月21日閲覧。

roszdravnadzor.gov.ru

“About the vaccine to prevent the novel coronavirus infection COVID-19, "Gam-COVID-Vac", developed by the National Research Centre for Epidemiology and Microbiology named after academician N. F. Gamalei of the Ministry of Health of the Russian Federation”. Federal Service for Surveillance in Healthcare (August 12, 2020). 2020年8月18日閲覧。
“Ministry of Health of the Russian Federation has issued a registration certification № ЛП-006395 dated August 11, 2020 for a vaccine to prevent the novel coronavirus infection COVID-19”. Federal Service for Surveillance in Healthcare (2020年8月11日). 2020年9月21日閲覧。

sciencemag.org

Cohen J (11 August 2020). “Russia's approval of a COVID-19 vaccine is less than meets the press release”. Science 13 August 2020閲覧。

sehiyye.gov.az

“Azerbaijan allowed for the first in the world to study a combination of "Sputnik V" vaccine and COVID-19 vaccine developed by "AstraZeneca" Company”. MoH of Azerbaijan (9 February 2021). 2020年2月26日閲覧。

sky.com

news.sky.com

“COVID-19: Moscow opens Sputnik V clinics – but 100,000 have already had it” (英語). Sky News

sptnkne.ws

“プーチン大統領が接種を受けたワクチンは？「スプートニクV」だったと公表”. スプートニク. (2021年6月30日). https://sptnkne.ws/GDDR 2021年7月8日閲覧。

sputnikvaccine.com

“Sputnik V authorized in Myanmar” (英語). sputnikvaccine.com. 2021年2月9日閲覧。

tass.com

“About 6.9 mln doses of Sputnik V vaccine to enter circulation in Russia by end of February”. TASS (December 10, 2020). 2020年9月21日閲覧。

telegraph.co.uk

Mullin J, Malnick E (1 August 2020). “Britain unlikely to use Russia's 'untrustworthy' Covid vaccine”. The Telegraph. オリジナルの19 August 2020時点におけるアーカイブ。 6 September 2020閲覧。

theglobeandmail.com

theguardian.com

theguardian.pe.ca

“Russia to vaccinate two million against COVID-19 in Dec - RDIF head to BBC”. Reuters (December 4, 2020). 2020年9月21日閲覧。

thelancet.com

themoscowtimes.com

trialsitenews.com

“Russia's RDIF & Prominent Government Lab Progress COVID-19 Vaccine: Production Facility Readied in the Moscow Region” (英語). trialsitenews.com (June 10, 2020). 2020年8月11日閲覧。

vedomosti.ru

Sokolov A (December 12, 2020). “Сколько хотят заработать на прививках от коронавируса”. Vedomosti. オリジナルの2020-08-12時点におけるアーカイブ。 2020年12月20日閲覧。.

vesti.ru

“Запущено производство российской антикоронавирусной вакцины” [Production of Russian anti-coronavirus vaccine launched] (ロシア語). Vesti (August 15, 2020). 2020年9月21日閲覧。

vox.com

Irfan U (11 December 2020). “Why staying cold is so important to a Covid-19 vaccine. The Moderna and Pfizer vaccines need to be stored at low temperatures. Are global health systems prepared?”. Vox. 27 December 2020閲覧。

washingtonpost.com

Taylor, Adam; Johnson, Carolyn Y.. “Russian vaccine Sputnik V more than 90% effective in interim trial”. Washington Post. ISSN 0190-8286 2021年2月9日閲覧。

web.archive.org

wikipedia.org

en.wikipedia.org

worldcat.org

search.worldcat.org

yomiuri.co.jp

“ロシア産ワクチン接種後に感染、アルゼンチン大統領にプーチン氏が「アフターケア」”. 読売新聞 (2021年4月6日). 2021年4月7日閲覧。

yucatan.com.mx

“Da la Cofepris autorización para que la vacuna Sputnik V se aplique en México” (スペイン語). Diario de Yucatán. (2 February 2021)